Clinical Trial Update: E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for E7 TCR cell induction immunotherapy in stage II/III HPV-associated oropharyngeal cancer; trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Neoplasms
• Papillomavirus Infections

Drugs mentioned

• E7 TCR cell induction immunotherapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Papillomavirus Infections, Oropharyngeal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-02-01